ChromaDex Corporation (CDXC) |
| 7.87 -0.07 (-0.88%) 03-18 16:00 |
| Open: | 7.91 |
| High: | 7.92 |
| Low: | 7.745 |
| Volume: | 541,672 |
| Market Cap: | 612(M) |
| PE Ratio: | 71.55 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
| sell | buy | |||
| Resistance 2: | |
| Resistance 1: | |
| Pivot price: | |
| Support 1: | |
| Support 2: | |
| 52w High: | 9.18 |
| 52w Low: | 2.305 |
ChromaDex Corporation is a bioscience enterprise committed to advancing healthy aging. The company's operations are segmented into three primary areas: Consumer Products, Ingredients, and Analytical Reference Standards and Services. Its research efforts largely concentrate on nicotinamide adenine dinucleotide (NAD+). Under its Consumer Products division, ChromaDex provides finished dietary supplements, which incorporate its proprietary ingredients, directly to consumers and through distributors. A flagship offering is TRU NIAGEN, a supplement featuring NIAGEN, the company's proprietary nicotinamide riboside (an NAD+ precursor) as its active component. The Ingredients segment is responsible for the development and commercialization of specialized ingredient technologies. It supplies these unique raw materials, including NIAGEN, to other manufacturers for use in their consumer products. Another significant ingredient is IMMULINA, composed of Braun-type lipoproteins and spirulina extracts, which is designed to support immune system function. Additionally, ChromaDex offers analytical reference standards and services. These products are vital for performing quality control checks on raw materials and finished goods within industries such as dietary supplements, cosmetics, food and beverages, life sciences, and pharmaceuticals. TRU NIAGEN products reach consumers via multiple channels, including ChromaDex's dedicated e-commerce site, TRUNIAGEN.com, as well as Amazon and other online marketplaces. Distribution also extends to specialty retailers and directly to healthcare practitioners within the United States. ChromaDex Corporation's main office is located in Los Angeles, California.
| EPS | |
| Book Value | |
| PEG Ratio | |
| Gross Profit |
| Profit Margin (%) | |
| Operating Margin (%) | |
| Return on Assets (ttm) | |
| Return on Equity (ttm) |
Thu, 13 Mar 2025
ChromaDex Corp. Announces Name Change to Niagen Bioscience, Inc. and New Ticker Symbol "NAGE" Effective March 19, 2025 - Business Wire
Tue, 15 Oct 2024
Yasmeen Nkrumah-Elie, Ph.D., Global Director of External Research at ChromaDex, Honored with the Trailblazing Woman Award by Radicle Science and Council for Responsible Nutrition (CRN) - Business Wire
Tue, 16 Jul 2024
ChromaDex Announces Pharmaceutical-Grade Intravenous and Injectable Niagen - Business Wire
Thu, 25 Apr 2024
ChromaDex Announces Nationwide Launch of Tru Niagen® at The Vitamin Shoppe® - Business Wire
Tue, 26 Mar 2024
ChromaDex Announces Tru Niagen® is Now Third-Party Verified Through the Alkemist Assured™ Transparency Program - BioSpace
Wed, 01 Nov 2023
(Patented Nicotinamide Riboside), One of the Most Efficient Nicotinamide Adenine Dinucleotide (NAD - Business Wire
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |